Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00808249 · ClinicalTrials.gov registry record · Phase 2

AZD7325 Proof of Concept in Patients With Generalized Anxiety Disorder (GAD)

A Phase 2 study of Anxiety Disorders, sponsored by AstraZeneca.

Completed
Registry status
Phase 2
Development phase
725
Enrollment target
20
Study locations

NCT00808249 is a Phase 2 study of Anxiety Disorders that has completed, run by AstraZeneca. The registered enrollment target is 725 participants, below the 1,131-participant average among 84 other Anxiety Disorders trials with a reported enrollment target (36% lower). The trial reports 20 study locations across 6 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00808249, a Phase 2 study of Anxiety Disorders, has completed, sponsored by AstraZeneca.

COMPLETED
Registry status
Phase 2
Development phase
725 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this research study is to determine whether AstraZeneca's drug AZD7325 is safe and effective in the treatment of generalized anxiety disorder.

Conditions Studied

Anxiety Disorders

Interventions

  • DRUG Placebo
  • DRUG AZD7325

Study Locations (20)

California

  • Research Site - Arcadia
  • Research Site - Beverly Hills
  • Research Site - Cerritos
  • Research Site - Chino
  • Research Site - Encino
  • Research Site - Los Alamitos
  • Research Site - Novato
  • Research Site - Oceanside
  • Research Site - San Diego

Florida

  • Research Site - Fort Myers
  • Research Site - Miami
  • Research Site - Pembroke Pines
  • Research Site - Saint Petersberg
  • Research Site - Tampa
  • Research Site - Winter Park

Georgia

  • Research Site - Atlanta
  • Research Site - Marietta

Alabama

  • Research Site - Birmingham

Arizona

  • Research Site - Tucson

Connecticut

  • Research Site - Norwich

Trial Details

FieldValue
Enrollment Target 725 participants
Start Date 2008-12
Est. Completion 2009-05
Phase Phase 2

Sponsor

AstraZeneca

1,285 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00808249

The ClinicalTrials.gov registry entry for NCT00808249 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 725 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,131-participant average among 84 other Anxiety Disorders trials with a reported enrollment target (36% lower). The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Anxiety Disorders appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT00808249 reports 20 study locations spanning 6 distinct geographic areas - top geographies include California, Florida, Georgia.

Frequently Asked Questions

What is clinical trial NCT00808249 about?

NCT00808249 is a clinical study titled "AZD7325 Proof of Concept in Patients With Generalized Anxiety Disorder (GAD)". The purpose of this research study is to determine whether AstraZeneca's drug AZD7325 is safe and effective in the treatment of generalized anxiety disorder.

What is the current status of trial NCT00808249?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 725 participants. The study started on 2008-12. Estimated completion is 2009-05.

What conditions does trial NCT00808249 study?

This clinical trial studies the following conditions: Anxiety Disorders.

What interventions are being tested in trial NCT00808249?

The interventions under investigation include: Placebo (DRUG), AZD7325 (DRUG).

Who is sponsoring clinical trial NCT00808249?

This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00808249 being conducted?

This trial has 20 study locations across Alabama, Arizona, California, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Anxiety Disorders

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Anxiety Disorders

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.